Spara
Antibody-Drug Conjugates
Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011).
- Undertitel
- The 21st Century Magic Bullets for Cancer
- Redaktör
- Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro
- Upplaga
- Softcover reprint of the original 1st ed. 2015
- ISBN
- 9783319376691
- Språk
- Engelska
- Vikt
- 310 gram
- Utgivningsdatum
- 6.10.2016
- Sidor
- 252
